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Abstract
Background: The purpose of this study was to discuss the clinical results which related to the location of giant cell
tumors (GCTs) in the pelvis so as to determine the ideal surgical treatment protocol.
Methods: We report 29 cases who accepted surgical treatment from five clinical centers during the last 12 years.
All patients were divided into three groups according to tumor locations, and they were also classified into two
groups in light of surgical treatments. The parameters for outcome evaluation consisting of general condition,
surgical complications, local disease control, and Musculoskeletal Tumor Society (MSTS) 93 functional score had
been analyzed, respectively.
Results: Surgical treatment in the acetabular area usually resulted in postoperative complications and poor function.
One patient who accepted intralesional surgery and two who accepted wide resection had local recurrence. The
mean functional score was 25.4 for the 8 patients who received intralesional surgery and 21.9 for the 21 patients who
received wide resection. Surgical complications occurred in 1 patient who underwent intralesional surgery and the
other 6 patients who underwent wide resection.
Conclusions: We conclude that surgical treatment of pelvic GCTs in the acetabular area is difficult to select as it is
always accompanied by complications and poor function. Compared to wide resection, intralesional surgery combined
with a meticulous preoperative planning may lower the recurrence rate and obtain favorable postoperative
functional results.
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Background
Giant cell tumors (GCTs) of the bone represent 3–8 %
of all primary bone tumors [1–3], most of which occur
at the ends of long bones. Accounting for only 1.5 to
6.1 % of bone GCTs [4–6], pelvic GCTs are rare lesions
and no more than 100 cases have been reported in the
past five decades before 2004 [7]. In the limited number
of literature, Guo et al. reviewed 27 cases with pelvic
GCTs, which is the largest series that had ever been
reported [8]. To our best knowledge, a multi-center clin-
ical study of GCTs has not been available in any publica-
tions. In this study, we collected the data of 29 cases
from five clinical institutions to analyze the correlation
between the location of GCTs in the pelvis and the
clinical results and to discuss the selection of surgical
treatment options.
There is still no widely held consensus in respect to
the ideal surgical treatment protocol for giant cell tu-
mors of the pelvis owing to their infrequent occurrence.
Due to the complex anatomy of the pelvis and mostly
delayed presence in clinical institution, the treatment for
pelvic GCTs might be challenging without a standard
treatment protocol for consultation. Treatment options
for pelvic GCTs include denosumab [9], serial embol-
ization [10], interferon [11], radiation therapy [12], and
intralesional curettage or wide resection [7, 13–16].
Although some primary treatments are favorable for
GCT control, it is still necessary to perform tumor resec-
tion if the lesion has become resectable. Strengths of
intralesional curettage include preservation of pelvic
integrity and avoidance of nerve disturbance, but it is
also deemed to increase the risk of local recurrence,
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especially for aggressive benign tumors [7, 13–16]. Al-
though wide resection is reported to minimize the
chance of local recurrence, this procedure seems to have
certain disadvantages such as long-time operation,
increased risk of nerve injury and infection, and
prosthesis-related complications from hip reconstruction
[17–19]. Some suggestions have been given in literatures
by retrospective analysis of their own treated patients,
but it is hard to say the treatments are not influenced by
their preference. Given the multi-center study of pelvic
GCTs has not been reported in any literatures, in this
study, we reviewed 29 cases treated by five bone tumor
experts from five institutions, which hopefully provides
information of great value to orthopedic surgeons and
assist them to select the optimal treatment protocol
from various options.
Methods
Five hundred thirteen patients with histologically benign
GCT of the bone were treated at these five institutions
from 2001 to 2013, of which 29 patients who presented
with pelvic GCT were retrospectively reviewed. In this
study, we included patients with the following criteria:
(1) pathological diagnosis of GCT was definite; (2) GCT
involved the pelvis but not the sacrum; (3) no prior
treatments of the tumor; and (4) complete clinical,
radiographic, and pathologic records. Most patients were
aged between the third and fourth decades of life at first
diagnosis, with a mean age of 39.2 years (range 15–
57 years). In this series, there were 14 males and 15 fe-
males with a mean follow-up period of 59 months (range
18–156 months) (Table 1). Eight patients were treated
with intralesional surgery while 21 underwent wide
resection. The patients’ data was collected from patient
records, surgical protocols, and histological and radio-
logical findings. The last follow-up was done via follow-
up exams after surgery or telephone contact.
The research was carried out according to the principles
set out in the Declaration of Helsinki 1964 and all subse-
quent revisions. Informed consent was obtained, and the
relevant institutional review board (Jinan Military General
Hospital Ethics Committee) had approved the study.
The diagnosis of GCT was established based on the
clinical data and imaging studies and confirmed by needle
biopsy or open biopsy before surgery as well as pathology
examination after surgery. In accordance with the classifi-
cation system for pelvic tumors by Enneking and Dunham
[17], further modified by Sanjay et al. [16], the locations of
tumor were divided into three types: type I (ilium), type II
(acetabulum), and type III (pubis/ischium). This study
included type I lesions in 10 patients, type II in 11
patients, and type III in 8 patients. Radiographical
classification system of Campanacci [20] categorizes the
lesion into three grades in which grade I indicates an
intraosseous lesion, grade II denotes an intraosseous
lesion with cortical thinning and expansile borders, and
grade III refers to a lesion extending extraosseously and
forming a soft tissue mass. There were 5 patients with
grade I lesions, 15 patients with grade II lesions, and 9
patients with grade III lesions included in this series. The
clinical results were statistically analyzed in light of
different GCT locations in the pelvis.
The treatment regimens were classified into group A
and group B, and group A had been further divided into
two subgroups. Group A1 included 5 patients treated by
intralesional curettage, of which two cases applied bone
cement to fill defect after curettage. Group A2 included
3 patients treated by microwave inactivation for the
GCT lesion before intralesional curettage, after which
defects were filled with autograft and allogeneic bone
graft (Fig. 1). Twenty-one patients treated by wide resec-
tion were included by group B, of which 3 patients in-
volving region I underwent reconstruction of the pelvic
ring after resection (Fig. 2) and 5 patients involving re-
gion II underwent rod fixation and total hip arthroplasty
(Fig. 3). One patient in group B involving region II ac-
cepted bone cement filling because of small bone defect,
while another patient involving region II accepted fem-
oral head exclusion after resection of pelvic tumors
around the acetabulum. The other 11 patients in group
B including 5 patients in region I and 6 patients in
region III did not receive any reconstruction after resec-
tion. The embolization procedure was not performed in
some cases as the tumor side of the common iliac artery
was temporarily blocked by a vascular clamp to control
bleeding during surgery. The effectiveness has been doc-
umented that the common iliac artery was mobilized
and encircled with nylon tape for temporary occlusion
during removal of the tumor [21]. Patients who accepted
microwave inactivation before curettage did not have
blood transfusion while most of the others had. Adju-
vant therapy such as chemotherapy or radiotherapy was
not used in the initial treatment in this series. One pa-
tient was treated with radiotherapy for the recurrent
tumor after surgery.
All patients had been requested to reexamine every
month for half a year after surgery, every 3 months in
0.5–2 years after surgery, and annually after 2 years. The
complications and local disease control were recorded
each time. Local recurrence was suspected initially by
evidence of new bone involvement assessed by radio-
graphs or computerized tomography (CT), and a biopsy
was further performed to confirm the suspicion. Musculo-
skeletal Tumor Society (MSTS) 93 score [22] had been
used for functional evaluation at the last follow-up in our
study. The MSTS 93 score measures patient activity, in-
cluding pain, function, emotional acceptance, supports,
walking ability, and gait. Each of these six variables was
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assessed on a five-point scale, giving a maximum score of
30 points. To some extent, higher MSTS score signifies
better functional results.
Results
Group A1: intralesional curettage (5 cases)
Group A1 was the simplest treatment regimen that
intralesional curettage was followed by bone cement
filling of the defect (cases 9 and 24) or not (cases 7, 25,
and 28). Three patients (cases 24, 25, and 28) demon-
strated good functions and were disease-free at follow-
ups. One patient (case 9) with ilium and acetabulum le-
sion who was primarily treated by intralesional curettage
and cementation suffered local recurrence 6 months
after surgery. The recurrence was confirmed by biopsy,
and he refused additional treatments although there is a
possibility of reoperation. He died of unclear cause with-
out any imaging and pathology 2 months later. One
Table 1 Clinical data and surgical results for 29 patients with GCTs involving the pelvis
No. Gender/
age (years)






1 F/39 I + II III Wide resection Rod fixation + THA 24 19 Recurrence
2 M/34 I + II III Wide resection Rod fixation + THA Wound healing
disturbance
136 22 No
3 F/33 I II Wide resection No 63 26 No
4 F/42 I + II III Wide resection Rod fixation + THA Wound healing
disturbance
12 17 Recurrence
5 M/47 III I Wide resection No 36 27 No
6 M/42 II + III III Wide resection Rod fixation + THA 22 16 No
7 F/43 II II Intralesional curettage No Limb shortening 156 18 No
8 F/25 I II Wide resection No 140 25 No
9 M/37 I + II III Intralesional curettage Cement 6 23 Recurrence
10 M/54 III II Wide resection No 56 22 No
11 M/57 III I Wide resection No 53 23 No
12 M/41 II + III III Wide resection Cement Delayed infection 49 18 No
13 F/41 II III Wide resection No Dislocation 38 14 No
14 F/15 II + III III Microwave + curettage Bone graft 148 28 No
15 F/34 II III Microwave + curettage Bone graft 37 26 No
16 F/42 III III Microwave + curettage Bone graft 21 28 No
17 M/50 III II Wide resection No 18 26 No
18 M/27 III III Wide resection No 30 24 No
19 M/46 III II Wide resection No 37 26 No
20 M/37 II + III III Wide resection Rod fixation + THA Wound healing
disturbance
18 21 No
21 F/50 I II Wide resection Pelvic ring
reconstruction
22 24 No
22 F/41 I II Wide resection No 26 22 No
23 M/33 I III Wide resection Pelvic ring
reconstruction
28 20 No
24 F/30 I II Intralesional
curettage
Cement 93 24 No
25 F/39 I II Intralesional curettage No 85 28 No





27 M/34 I III Wide resection No 60 22 No
28 F/38 III II Intralesional curettage No 56 28 No
29 F/55 I II Wide resection No 28 24 No
M male, F female, THA total hip arthroplasty
aAccording to the classification system of Enneking and Dunham
bAccording to the Campanacci grading system
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patient (case 7) with acetabulum lesion underwent limb
shortening. At 3-year follow-up, the patient was free
from pain, but she limped and leaned on a cane for lon-
ger walks due to the 5-cm shortening. As the shortening
gradually worsened, total hip arthroplasty was under-
taken for her at 5 years after primary surgery.
Group A2: microwave inactivation for the GCT lesion
before intralesional curettage (3 cases)
Three patients (cases 14, 15, and 16) with partial acetabu-
lum lesion underwent microwave inactivation before intra-
lesional curettage, after which defects were filled with
autograft and allogeneic bone graft. They remained disease-
free and had no functional limitation at follow-ups. No
recurrence and complications were found in this group.
Group B: wide resection (21 cases)
The 5 patients with tumors of region I (cases 3, 8, 22,
27, and 29) were treated by wide resection of the iliac
tumor without reconstruction whereas the other 3 pa-
tients with tumors of region I (cases 21, 23, and 26) were
treated by wide resection with pelvic ring reconstruction.
The 6 patients with tumors of region III (cases 5, 10, 11,
17, 18, and 29) underwent wide resection without recon-
struction. The 5 patients with tumors of region II (cases
1, 2, 4, 6, and 20) received wide resection with rod
fixation and total hip arthroplasty whereas the other 2
patients (cases 12 and 13) received wide resection with-
out reconstruction. One patient (case 4) who had wide
resection suffered local recurrence at 12 months after
surgery, and she accepted hemipelvectomy after biopsy
confirmation as well as radiation therapy for pulmonary
metastasis 2 months after hemipelvectomy. Unfortu-
nately, she died of metastasis. One patient (case 1) who
underwent resection of the tumor in regions I and II re-
curred in region III at 18 months after surgery, and she
died of unclear cause at half a year after recurrence
without additional treatments and imaging examination.
Fig. 1 a Plain film of a 15-year-old female demonstrates an osteolytic lesion in the left periacetabular region. b CT scan presents the tumor involvement
in the acetabulum, but the acetabulum cartilage and bone below it can be preserved. c Sketch illustrates that microwave inactivation was employed
for this patient before intralesional curettage. d Plain film at 6 months after operation shows a suspicious lesion in the left pubis. No treatment was
performed as there is no presentation of pain or other discomfort. e CT scan at 4 years after operation manifests that the intumescent lesion in the left
pubis has mineralized edge. f Plain film at 11 years after operation shows no recurrence. g, h The patient had good function without any discomfort in
the last follow-up
Fig. 2 Case presentation of a 32-year-old male presented a persistent pain of the left ilium for 3 months. a Osteolytic lesions can be observed in
the left ilium on the plain film. b CT scan shows the tumor involvement in the ilium where a huge soft tissue mass formed. c The tumor was
resected widely, and the inferior cut line was at the normal bone above the acetabulum. d Screws and rods were used for reconstruction of the
pelvic ring after tumor resection
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Four patients (cases 2, 4, 20, and 26) with wound healing
problems were managed by debridement with eventual
healing between 4 and 6 weeks. Dislocation of the hip
occurred in 1 patient (case 13) with femoral head exclu-
sion after resection of pelvic tumors around the acetabu-
lum, and she got local stability after long periods of bed
rest. This patient could walk with crutches with no pain
at the most recent follow-up. One patient (case 12) with
a delayed infection eventually healed after wound de-
bridement for three times and long-term antibiotic use.
GCT locations in the pelvis seem to be an influence
factor regarding the surgical complications and MSTS
functional score. Surgical complications were much
more common, and the MSTS functional score was
lower when the GCTs involved the acetabulum than
those in the ilium or pubis/ischium (p = 0.010, p = 0.005)
(Table 2).
The mean MSTS functional score at the last follow-up
was 22.8 (range 14–28) with a mean score of 25.4 for 8
patients who underwent intralesional surgery and 21.9
for 21 patients treated with wide resection. Some param-
eters were used for statistical analyses between group A
(intralesional surgery) and group B (wide resection), but
significant difference could only be found in the MSTS
functional score (p = 0.024) (Table 3).
Discussion
Giant cell tumors of the bone rarely affect the pelvis, with
an incidence of only 1.5 to 6.1 % of bone GCTs [4–6].
Only 73 pelvic lesions had reported in literatures from
1949 to 1999 [7], and the largest number of cases with pel-
vis GCTs presented in one study was no more than 30. In
this study, 29 patients with pelvis GCTs from five institu-
tions had been collected for analysis. To our knowledge, it
is the largest number of cases in the existing literatures as
well as the only multi-center study on pelvis GCTs.
The local recurrence rate for giant cell tumors of the
pelvis seems to be higher than that of any other location
in the skeleton for western or eastern [23, 24], due to
the complex anatomy and the large size these lesions
can attain before diagnosis. The local recurrence rate
can be as high as 43 % for therapeutic options other
than wide resection [7, 13–16, 25]. Sanjay et al. [16] re-
ported that 3 of 15 patients with pelvic GCTs had local
recurrence after intralesional surgery, whereas no one
recurred in 2 patients who underwent wide resection.
Balke et al. [13] reported that 1 of 16 patients with pelvic
GCTs suffered local recurrence after intralesional sur-
gery, whereas none of 3 patients with wide resection
recurred. Guo et al. [8] reported that 4 of 13 patients
with pelvic GCTs had local recurrence after intralesional
surgery, whereas 0 of 14 patients suffered recurrence
after wide resection. In our study, 2 of the 21 patients
who underwent wide resection had local recurrences,
whereas one of 8 patients who underwent intralesional
surgery had local recurrence. No significant difference in
recurrence was found between intralesional surgery and
wide resection (p = 0.814). It is generally accepted that
wide resection can reduce the risk of recurrence because
the adjacent tissue can be resected with the tumor to
achieve an adequate resection margin. For some pelvic
GCTs, wide resection is hard to perform owing to the
complex anatomic structures in the pelvis. Intralesional
surgery is an adequate option for some patients based
on careful preoperative planning. Initial surgical treat-
ment is of great importance to patients on account of
the fact that recurrence of the tumor may make it unre-
sectable; as a consequence, it is vital for patients with
pelvic GCTs to be operated by surgeons with sufficient
knowledge of bone tumor. The tumor size and Campa-
nacci classification should be taken into account in the
preoperative plan. If the tumor is not limited to one re-
gion defined by the Enneking and Dunham classification
system for pelvic tumors, we believe wide resection
could be a reasonable choice. If the Campanacci classifi-
cation is grade III that the bone walls are destroyed by
the tumor and a large soft tissue mass forms, wide resec-
tion is recommended to ensure a safe margin.
Treatment options for pelvic GCTs include denosu-
mab, serial embolization, interferon, radiation therapy,
Fig. 3 Case presentation of a 34-year-old man who mainly complained about pain in the left hip area for 5 months which was aggravated over
the previous 1 week. a Osteolytic lesions can be observed in the left ilium and periacetabular region on the plain film. b The tumor was resected
widely, and the cut line was at the normal bone. c A plain film at 2 years after operation shows no recurrence. d The patient has good function
without any discomfort in the last follow-up
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and surgical treatment. Denosumab is a fully humanized
monoclonal antibody against the RANK ligand which has
demonstrated significant activity in patients with unresect-
able or recurrent GCTs in the bone [9]. Denosumab was
approved by the FDA for the treatment of adults and
skeletally mature adolescents with GCT of the bone that
is unresectable or where surgical resection is likely to re-
sult in severe morbidity in 2013. However, patients did
not accept the denosumab treatment in China because the
denosumab was not approved by CFDA and the patients’
agreement was hard to get. Although serial embolization
[10] and interferon [11] have been accepted in the GCT
treatment, it is still necessary to perform surgical treat-
ment thereafter. The obvious advantage of radiation ther-
apy is the avoidance of additional surgical morbidity,
while its disadvantages include local effects of radiation
therapy and the potential for radiation-induced sarcoma.
Leggon et al. [7] reviewed literatures of pelvic and sacral
GCTs, which revealed that patients treated with radiation
therapy had an incidence of 44 % of local recurrence and
12 % of radiation-induced sarcoma.
Therefore, it is quite clear that surgery plays an unpar-
alleled role in the pelvis GCT treatments. It is widely
accepted that intralesional surgery can spare nerve roots,
pelvic support, and the hip and visceral structures,
whereas it has a high risk of local recurrence, even for a
recurrent GCT. Various adjuvant modalities have been
used to supplement intralesional surgery in order for a
low recurrence rate, which include the use of cytotoxic
agents such as phenol [16], zinc chloride [26], ethanol
[14], and physical adjuvants such as polymethylmetha-
crylate [13, 14, 27], cryosurgery [13], microwave inacti-
vation [28], and a high-speed burr drill [13, 14]. Besides,
a study shows that curettage based on CT classification
can also lower the recurrence rate [29]. In this series,
microwave inactivation had been employed for 3
patients before intralesional surgery and no recurrence
occurred. It is obvious that microwave inactivation is
performed before surgery other than other adjuvant
treatments. The inactived tumor tissues do not have
viable cells during curettage in theory. The difficulties
for this method include protection of the surrounding
normal tissues and complete inactivation for the whole
tumor tissue. Furthermore, GCTs did not destroy the
subchondral bone in the acetabular area for these 3 pa-
tients. We used polymethylmethacrylate for 2 patients in
Table 2 The statistic analyses of 29 pelvic GCT patients basing on the location group
Categories Type Ia Type IIa Type IIIa Total p
Number, n (%) 10 (34.5) 11 (37.9) 8 (27.6) 29 (100) –
Age, year, means (SD) 37.2 (9.3) 36.8 (7.9) 45.1 (9.5) 39.2 (9.3) 0.106
Age group, n (%) 0.175
<20 0 (0) 1 (9.1) 0 (0) 1 (3.4)
20~29 1 (10.0) 0 (0) 1 (12.5) 2 (6.9)
30~39 6 (60.0) 5 (45.5) 1 (12.5) 12 (41.4)
40~49 1 (10.0) 5 (45.5) 3 (37.5) 9 (31.0)
≥50 2 (20.0) 0 (0) 3 (37.5) 5 (17.2)
Sex, n (%) 0.160
Male 3 (30.0) 5 (45.5) 6 (75.0) 14 (48.3)
Female 7 (70.0) 6 (54.5) 2 (25.0) 15 (51.7)
Treatment, n (%) 0.691
S (IL) 2 (20.0) 4 (36.4) 2 (25.0) 8 (34.5)
S (W) 8 (80.0) 7 (63.6) 6 (75.0) 21 (31.0)
Follow-up, months, means (SD) 62.2 (38.0) 75.5 (59.9) 38.3 (15.3) 59.0 (42.7) 0.215
Recurrence, n (%) 0.065
Exist 0 (0) 3 (27.3) 0 (0) 3 (10.3)
None 10 (100) 8 (72.7) 8 (100) 26 (89.7)
Complication, n (%) 0.010
Exist 1 (10.0) 6 (54.5) 0 (0) 7 (24.1)
None 9 (90.0) 5 (45.5) 8 (100) 22 (75.9)
MSTS, means (SD) 23.6 (2.4) 20.2 (4.3) 25.5 (2.3) 22.8 (3.8) 0.005
S (IL) intralesional curettage, S (W) wide resection
aAccording to the classification system of Enneking and Dunham
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order for filling and inactivation, one of which suffered
recurrence. The high-speed burr drill was employed in 2
patients to deal with residual GCT cells that may remain
on the surface of the curettage cavity, and no recurrence
occurred. We did not use nitrogen or other chemicals
for the sake of avoiding chemical injury to the surround-
ing tissues from leaking adjuvants. Wide resection has
been thought to minimize the chance of local recur-
rence, which is true for tumors in regions I and III, ra-
ther than the ones in region II. There is no doubt that
wide resection is difficult to perform for large-size pelvic
GCTs, especially those involving region II. An increased
surgical morbidity is usual even for an experienced bone
tumor surgeon.
The MSTS 93 score had been applied for patients’
functional evaluation in this study. Compared with intra-
lesional surgery, the function of the patients who ac-
cepted wide resection appeared worse. However, it was
not absolute for all patients that most patients who ac-
cepted wide resection for GCTs in regions I and III had
good functions. For the GCTs involving region II or
more than one region, favorable functional results were
hard to achieve although some specialized prostheses
had been developed to reconstruct the defect after ace-
tabular bone resection. In this series, we preferred to use
screws, titanium rods, and bone cement to reconstruct
the integrity of the pelvis based on our experience. The
advantages of this method include simple instruments,
flexible fixed way, and relatively stable mechanical
strength. The disadvantages include fixation loosening
and breakup. The fixation-related complications were
not observed in our patients, and most patients who ac-
cepted pelvis reconstruction could resume their routine
activities within 3 months after surgery.
As we know, complications are common for pelvis
tumor because of wide wound exposure, extensive soft
tissue stripping, implant existence, local hematoma for-
mation, and poor skin flap blood supply [30]. In this
study, wound healing disturbance was the major compli-
cation, which occurred in 4 patients who underwent
wide resection and pelvis reconstruction. Limb shorten-
ing, delayed infection, and dislocation happened in 3 pa-
tients, respectively. It is obvious that patients with GCTs
in region II had a higher incidence of complication com-
pared with those in regions I and III. For reducing com-
plications, it is necessary to protect the skin flap and
reduce soft tissue tension. Otherwise, drainage is very
important for postoperative care.
It is necessary to alert readers to be aware of the limi-
tations of this study. Firstly, the number of patients is
still small although it is the largest series among the
reports owing to the fact that pelvic GCTs are rare. It is
hard to make any definitive statements regarding the dif-
ferences of recurrences, complications, and postopera-
tive function among different treatments without large
sample statistical analysis. Secondly, this is a multi-
centric retrospective study and the patients’ treatments
were decided by five experienced bone tumor surgeons,
respectively; consequently, the differences among surgical
technologies cannot be avoided. Nevertheless, consensuses
of treatments had been made by these surgeons, and post-
operative situations of different treatment methods may
provide valuable information for surgeons in the decision-
making process. Thirdly, the minimum follow-up is short
and additional local recurrences might occur with longer
follow-ups. Nevertheless, 70 % of local recurrences occur
within 2 years [31].
Treatment of pelvic GCTs remains a challenge for sur-
geons, especially for the ones involving region II. In this
study, patients with GCTs that did not destroy the sub-
chondral bone in region II achieved good functions and
suffered no recurrence by undergoing microwave inacti-
vation before intralesional surgery. Therefore, it could be
an alternative treatment for some patients, although it
should be determined on the basis of sufficient clinical
Table 3 The statistic analyses of 29 pelvic GCT patients basing
on the treatment group
Categories S (IL) S (W) Total p
Number, n (%) 8 (27.6) 21 (72.4) 29 (100) –
Age, year, means (SD) 34.8 (9.0) 41.0 (9.0) 39.2 (9.3) 0.732
Age group, n (%) 0.190
<20 1 (12.5) 0 (0) 1 (3.4)
20~29 0 (0) 2 (9.5) 2 (6.9)
30~39 5 (62.5) 7 (33.3) 12 (41.4)
40~49 2 (25.0) 7 (33.3) 9 (31.0)
≥50 0 (0) 5 (23.8) 5 (17.2)
Sex, n (%) 0.035
Male 1 (7.1) 13 (92.9) 14 (48.3)
Female 7 (46.7) 8 (53.3) 15 (51.7)
Location,a n (%) 0.691
I 2 (25.0) 8 (38.1) 10 (34.5)
II 4 (50.0) 7 (33.3) 11 (52.4)
III 2 (25.0) 6 (28.6) 8 (27.6)
Follow-up, months,
means (SD)
85.1 (52.1) 49.3 (35.4) 59.0 (42.7) 0.056
Recurrence, n (%) 0.814
Exist 1 (12.5) 2 (9.5) 3 (10.3)
None 7 (87.5) 19 (90.5) 26 (89.7)
Complication, n (%) 0.635
Exist 1 (12.5) 6 (28.6) 7 (24.1)
None 7 (87.5) 15 (71.4) 22 (75.9)
MSTS, means (SD) 25.4 (3.6) 21.9 (3.5) 22.8 (3.8) 0.024
S (IL) intralesional curettage, S (W) wide resection
aAccording to the classification system of Enneking and Dunham
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evidence; as a consequence, a prospective study about
the clinical efficacy of microwave inactivation for GCTs
has already been launched by our team. It has great diffi-
culties to achieve balance among recurrence, complica-
tions, and functions for the GCTs with benign histology
and aggressive biological behavior; thus, detailed commu-
nication with patients is essential during the decision-
making process.
Conclusions
There are only a few case reports in the literature and
no large numbers of clinical trials about treatment of,
and research into, pelvic GCTs. In this study, low recur-
rence rate and favorable postoperative functional results
of pelvic GCTs were obtained successfully through intra-
lesional curettage, combined with a meticulous pre-
operative planning. Due to the small sample size of this
study, the results should be examined cautiously. Larger,
high-quality clinical trials are required to strengthen and
verify these conclusions.
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